Vera Therapeutics director Hite files Form 3

Vera Therapeutics, Inc. director Christopher Hite filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 03/09/2026 - 04:47 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vera Therapeutics, Inc. director Christopher Hite filed an initial ownership report on Form 3. The data provided lists him as a director of the company and shows no reportable stock transactions or holdings in the transaction section of the filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Vera Therapeutics (VERA) Form 3 for Christopher Hite show?

The Form 3 lists Christopher Hite as a director of Vera Therapeutics. The transaction section is empty in the provided data, indicating no reportable transactions or share movements in this filing excerpt.

Does the VERA Form 3 for Christopher Hite show any share purchases or sales?

No share purchases or sales are shown for Christopher Hite in this Form 3 excerpt. The transaction summary reports zero buy, sell, acquire, dispose, and other transactions, with net buy/sell shares reported as 0.

What roles are reported for Christopher Hite in Vera Therapeutics’ Form 3?

Christopher Hite is reported as a director of Vera Therapeutics in this Form 3. He is not listed as an officer, not identified as a ten percent owner, and has no other roles disclosed in the provided data.

What does the transaction summary indicate in the VERA Form 3 filing?

The transaction summary shows zero transactions across all categories for Christopher Hite. Buy, sell, acquire, dispose, and other counts are all 0, and the net buy/sell direction is listed as neutral with 0 net shares.

Are there any notable footnotes in the Vera Therapeutics Form 3 for Christopher Hite?

The Form 3 excerpt includes a footnotes section, but it contains only an empty entry. No additional explanatory information or ownership disclaimers are provided in the footnotes text shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/05/2026

3. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Joseph R. Young, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.